Project description:Background: Parkinson's disease (PD), a neurodegenerative disease characterised by bradykinesia, rest tremor and rigidit, affects approximately 6.1 million people worldwide. Although its aetiology was attributed to accumulation of misfolded alpha-synuclein species and subsequent loss of dopaminergic neurons in the substantia nigra, recently, systemic factors contributing to its initiation and progression have gained increasing recognition. Specifically, exosomes, a kind of extracellular vesicles in the size range of ∼30 to ∼200 nm, have been highlighted as crucial mediators in orchestrating the intricate intercellular communication in PD. Among its cargos, miRNAs, with its ability to promote target mRNA degradation and inihibit translation, have been identiifed as promising biomarkers and therpaeutic targets. Nonetheless, the effect of anti-parkinsonism medication on the serum exosome miRNA profiles of PD patients remain lagrely unexplored. Objective: To examine the effects of rasagiline, a potentially neuroprotective monoamine oxidase B inihibitor, on the serum exosome miRNA profile of PD patients.

2024-07-26 | GSE269776 | GEO

Effect of rasagiline on the serum exosome miRNA transcriptome of Parkinson's disease patients (2023)

2024-07-26 | GSE269779 | GEO

Effect of rasagiline on the serum exosome miRNA transcriptome of Parkinson's disease patients (2022)

2024-07-26 | GSE269777 | GEO

Effect of rasagiline on the serum exosome miRNA transcriptome of Parkinson's disease patients (2020)

2024-07-26 | GSE269775 | GEO

CIDR:NGRC PARKINSON'S DISEASE STUDY

Project description:CIDR:NGRC PARKINSON'S DISEASE STUDY

| PRJNA75909 | ENA

miRNA seq

Project description:miRNA seq